Compare FRSH & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSH | OGN |
|---|---|---|
| Founded | 2010 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.6B |
| IPO Year | 2021 | 2020 |
| Metric | FRSH | OGN |
|---|---|---|
| Price | $12.04 | $13.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 4 |
| Target Price | ★ $16.62 | $10.33 |
| AVG Volume (30 Days) | ★ 5.0M | 2.3M |
| Earning Date | 11-03-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | ★ 296.88 | N/A |
| EPS | 0.06 | ★ 1.56 |
| Revenue | $838,809,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | $13.96 | $2.07 |
| P/E Ratio | $203.75 | ★ $8.87 |
| Revenue Growth | ★ 16.43 | N/A |
| 52 Week Low | $6.79 | $5.69 |
| 52 Week High | $15.51 | $13.88 |
| Indicator | FRSH | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.67 | 62.71 |
| Support Level | $11.83 | $13.72 |
| Resistance Level | $12.20 | N/A |
| Average True Range (ATR) | 0.63 | 0.04 |
| MACD | -0.40 | 0.01 |
| Stochastic Oscillator | 3.61 | 82.14 |
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions. It derives maximum revenue from North America.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.